Breaking News

Aenova Invests in New Building for the Production of Highly Potent Drugs

Increases production capacity to meet market demand with an investment of roughly €10 million at Regensburg site.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cytotoxics and cytostatics continue to experience increased demand in the global pharmaceutical market. To meet this growing demand, Aenova, a global development service provider and contract manufacturer for the pharmaceutical and healthcare industries, is building a new facility at its Regensburg, Germany site. The investment of around €10 million will enable the company to expand the production in the field of highly potent active ingredients and, in particular, cancer drugs. The foundation s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters